Targeting hepcidin or the inflammatory pathways that elevate its levels presents a promising therapeutic approach to address anemia and tumor progression, potentially improving cancer patients’ quality of life and clinical outcomes [54,55]. This evidence concerns the gene HAMP and anemia (phenotype).